Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Parathyroid Glands00:59

The Parathyroid Glands

The two pairs of parathyroid glands embedded within the posterior surface of the thyroid gland are restricted by a dense capsule around them. These glands comprise two distinct cell populations—parathyroid oxyphil and parathyroid principal cells- pivotal in calcium homeostasis.
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by producing...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Model-based somapacitan dosing and IGF-I response in children born SGA or with ISS, Noonan or Turner syndromes.

Journal of the Endocrine Society·2026
Same author

Social Inequalities in Infant Mortality Related to Congenital Anomalies: A Population-Based Register Study.

Paediatric and perinatal epidemiology·2026
Same author

Continuous subcutaneous recombinant PTH(1-34) infusion improves serum calcium and phosphate homeostasis in children with autosomal dominant hypocalcemia type 1 refractory to standard-of-care treatment.

European journal of endocrinology·2026
Same author

Excluding children: What "no-kids zones" reveal about our collective future.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2026
Same author

Safety, tolerability, pharmacokinetics, and efficacy of burosumab in infants with X-linked hypophosphataemia: an open-label, multicentre, non-randomised study.

The lancet. Diabetes & endocrinology·2026
Same author

Risk of bone overstimulation in long-term PTH(1-34) therapy for hypoparathyroidism.

European journal of endocrinology·2026
Same journal

Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation.

Endocrine·2026
Same journal

Effects of a single-dose denosumab on glucose and lipid homeostasis in young infertile men.

Endocrine·2026
Same journal

Ultrasound-guided thermal ablation for papillary thyroid microcarcinoma with calcifications: short-term imaging outcomes.

Endocrine·2026
Same journal

Diabetic gastroparesis: pathophysiology and impact on insulin timing choices.

Endocrine·2026
Same journal

Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center.

Endocrine·2026
Same journal

Interpreting the TIR 3B nomogram as a rule-in rather than rule-out tool.

Endocrine·2026
See all related articles

Related Experiment Video

Updated: May 11, 2026

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

Primary hyperparathyroidism in pregnancy.

Gonzalo Diaz-Soto1, Agnès Linglart, Marie-Victoire Sénat

  • 1Service d'Endocrinologie et des Maladies de la Reproduction, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Hôpital de Bicêtre, 94275, Le Kremlin Bicêtre, France.

Endocrine
|May 15, 2013
PubMed
Summary
This summary is machine-generated.

Primary hyperparathyroidism (PHPT) in pregnancy poses risks to mothers and babies. Parathyroidectomy in the second trimester is often recommended for severe cases, while mild forms may be managed conservatively.

More Related Videos

Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging
07:12

Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging

Published on: August 17, 2022

Related Experiment Videos

Last Updated: May 11, 2026

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging
07:12

Establishment of a Simple and Effective Rat Model for Intraoperative Parathyroid Gland Imaging

Published on: August 17, 2022

Area of Science:

  • Endocrinology
  • Obstetrics
  • Maternal-Fetal Medicine

Background:

  • Primary hyperparathyroidism (PHPT) is uncommon during pregnancy but linked to severe maternal and fetal complications.
  • Existing management guidelines are limited due to scarce clinical data.

Purpose of the Study:

  • To review the literature on PHPT in pregnancy and outline management strategies.
  • To identify high-risk pregnancies and inform treatment decisions.

Main Methods:

  • Literature review of key articles on PHPT in pregnancy up to December 2012.
  • Focus on large case series and retrospective studies.

Main Results:

  • Diagnosis of PHPT in pregnancy is challenging due to non-specific hypercalcemia symptoms.
  • High maternal and fetal risks exist for calcium levels >2.85 mmol/L, including loss.
  • Neonatal hypocalcemia and tetany affect approximately 50% of infants born to untreated mothers.

Conclusions:

  • Management should be individualized based on gestational age and hypercalcemia severity.
  • Parathyroidectomy during the second trimester is supported for serum calcium >2.75 mmol/L.
  • Conservative management (hydration, vitamin D) is suitable for mild PHPT cases.